

REDUCING DISEASE ONSET AND HEALTHCARE COSTS

OMADA's GLP-1 SOLUTIONS vs. STANDARD CARE

Comparison of clinical and economic outcomes

6+ months of medication persistence while enrolled in Omada's GLP-1 solutions can reduce disease onset by up to 52%

Members with 12+ months of persistence are included in the ≥6 month group

OVER 6 MONTH PERSISTENCE

12.4%

Average 12-month weight loss

\$8,578

Medical cost savings over 5 years

OVER 12 MONTH PERSISTENCE


17%

Average 12-month weight loss


\$11,142

Medical cost savings over 5 years

REDUCTION IN DISEASE ONSET OVER 5 YEARS



CUMULATIVE MEDICAL COST SAVINGS



All figures are gross medical cost savings vs. standard care and do not include the cost of GLP-1 medication

Medical cost savings vs. standard care grow with GLP-1 persistence

Savings grow the longer members stay on GLP-1 therapy



Six months of persistence drives meaningful savings. These savings grow further with continued persistence, highlighting the value of supporting members through this critical early window.

Projections based on a Disease Prevention Microsimulation Model (DPMM), comparing modeled outcomes for individuals persisting on GLP-1 therapy while enrolled in Omada's GLP-1 solutions vs. the same population's standard care counterfactual